- Home
- PCVX
PCVX
Vaxcyte Inc.
as 02-21-2025 12:41pm EST
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
Upcoming Earnings Alert:
Get ready for potential market movements as Vaxcyte Inc. PCVX prepares to release earnings report on 25 Feb 2025.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SAN CARLOS |
| Market Cap: | 11.5B | IPO Year: | 2020 |
| Target Price: | $127.71 | AVG Volume (30 days): | 884.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $58.10 - $121.06 | Next Earning Date: | 02-25-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Vaxcyte Inc. (PCVX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW | PCVX | PRESIDENT AND CFO | Feb 18 '25 | Sell | $84.11 | 8,000 | $670,822.74 | 109,491 | |
| Eydelman Mikhail | PCVX | SVP, GEN COUNSEL & CORP SEC | Feb 5 '25 | Sell | $89.91 | 5,000 | $450,368.64 | 32,016 | |
| Wassil Jim | PCVX | CHIEF OPERATING OFFICER | Feb 3 '25 | Sell | $86.87 | 8,000 | $689,790.43 | 205,715 | |
| GUGGENHIME ANDREW | PCVX | PRESIDENT AND CFO | Jan 21 '25 | Sell | $87.01 | 8,000 | $692,100.57 | 109,491 | |
| Loxam Teri | PCVX | Director | Jan 15 '25 | Sell | $84.54 | 6,250 | $531,962.92 | 13,279 | |
| Eydelman Mikhail | PCVX | SVP, GEN COUNSEL & CORP SEC | Jan 6 '25 | Sell | $85.70 | 5,000 | $427,922.80 | 32,016 | |
| Wassil Jim | PCVX | CHIEF OPERATING OFFICER | Jan 2 '25 | Sell | $83.67 | 8,000 | $669,266.91 | 205,715 | |
| GUGGENHIME ANDREW | PCVX | PRESIDENT AND CFO | Dec 18 '24 | Sell | $88.88 | 8,000 | $710,248.58 | 109,491 | |
| PICKERING GRANT | PCVX | CHIEF EXECUTIVE OFFICER | Dec 9 '24 | Sell | $92.70 | 2,366 | $218,252.88 | 136,215 | |
| Eydelman Mikhail | PCVX | SVP, GEN COUNSEL & CORP SEC | Dec 5 '24 | Sell | $91.66 | 5,000 | $457,433.92 | 32,016 |
Latest Vaxcyte Inc. News
PCVX Breaking Stock News: Dive into PCVX Ticker-Specific Updates for Smart Investing
Investor's Business Daily
8 days ago
It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care
GlobeNewswire
9 days ago
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
Investor's Business Daily
9 days ago
RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care.
Insider Monkey
13 days ago
Why Vaxcyte, Inc. (PCVX) Is Among the Best Healthcare Stocks To Buy According to Analysts
MT Newswires
14 days ago
Vaxcyte Insider Sold Shares Worth $450,369, According to a Recent SEC Filing
TipRanks
15 days ago
Vaxcyte advances second stage of Phase 2 study evaluating VAX-31
Clinical Trials Arena
15 days ago
Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants
MT Newswires
16 days ago
Vaxcyte Advances Phase 2 Study on Infant Pneumococcal Disease Prevention to Final Stage
Compare PCVX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PCVX Vaxcyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.